THIS STUDY IS UNDERTAKEN TO ASSESS THE EFFECT OF PRETREATMENT WITH ROCURONIUM BROMIDE IN PREVENTING ETOMIDATE INDUCED MYOCLONUS DURING ANAESTHETIC INDUCTION .AS ETOMIDATE IS A NOVEL ANAESTHESTHETIC AGENT WITH MYOCLONUS AS THE ONLY LIMITING FACTOR
Phase 2
- Conditions
- Health Condition 1: K819- Cholecystitis, unspecified
- Registration Number
- CTRI/2020/02/023506
- Lead Sponsor
- BMCRI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA physical status 1 and 2 . Patients who gave written informed consent.
Exclusion Criteria
Patients not willing to participate in the study, Patients with cardiovascular disease,respiratory disease,hepatic , renal and adrenal disease and epilepsy. Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MyoclonusTimepoint: At 1-3 min after etomidate injection
- Secondary Outcome Measures
Name Time Method Pain on injectionTimepoint: at the time of etomidate injection